MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00370474
Recruitment Status : Terminated (Procedure protocol improved - study protocol became obsolete)
First Posted : August 31, 2006
Last Update Posted : June 18, 2007
Information provided by:

Brief Summary:
Magnetic navigation will permit delivery of the LV lead tip to a prospectively defined location more efficiently and in a higher proportion of patients than is possible with manual navigation.

Condition or disease Intervention/treatment Phase
Cardiac Resynchronization Therapy Device: Bi-ventricular lead placement Phase 4

Detailed Description:

MAGNET CRT is designed to compare magnetic navigation to manual (i.e., traditional) navigation in placing an over-the-wire (OTW)left ventricle (LV) lead at a target site identified by the investigator. This is a prospective, randomized, multicenter trial in which randomization (2:1, magnetic: manual navigation) will occur after the patient-specific target site is identified on two hardcopy x-ray images of the coronary venogram. The target area will be identified upon review of a venogram of the patient’s coronary venous system taken during the current procedure.

Other variables such as navigating through the vasculature to a potential target site (especially if the path is tortuous), achieving good contact with the myocardium, providing repositioning if needed, countering heart motion, retrograde blood flow, and maintaining a stable delivery system during the release of the lead, are all determinants in the success of LV lead placement.

The Magnetic Navigation System (MNS) may thus aid in coronary venous vasculature navigation of guidewires for over-the-wire (OTW) left ventricular (LV) pacing lead placement by assisting in directing the tip of the guidewire, regardless of the tortuosity of a given patient’s anatomy.

No investigational products will be used in the conduct of this study. The Niobe® Magnetic Navigation System and all Stereotaxis guidewires and other disposable products to be utilized have received US marketing clearance, and the protocol applications are within their specified intended use.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-Center Assessment of Gain in Navigation Efficiency To Cardiac Resynchronization Therapy
Study Start Date : June 2006
Actual Study Completion Date : September 2006

Primary Outcome Measures :
  1. The first primary endpoint for this trial is LV lead placement time defined as time from entry of the guidewire into the coronary sinus os to confirmed positioning of the lead tip at the target site
  2. The second primary endpoint will be time from introduction of the LVlead into the introducer sheath to positioning of the lead tip at the target site.

Secondary Outcome Measures :
  1. Secondary endpoints include
  2. Skin to Skin time (Time of first skin incision to skin closure)
  3. Success in lead positioning to posterior-lateral location or other identified initial target or other identified initial target determined by 3-month lead-related complication free rate > 80%
  4. Percent of cases with stable lead placement as noted by appropriate sensing and pacing thresholds. by using a pacing system analyzer (PSA)
  5. peri-operatively and pulse generator post-operatively (mean 3-month:
  6. pacing threshold < 2.5 V, amplitude > 3/0 mV, pacing impedance
  7. > 300 Ώ)
  8. Procedural success, defined as the ability to complete the procedure.
  9. CC’s of contrast utilized for the procedure.
  10. Total procedure fluoroscopy time.
  11. LV lead placement fluoroscopy time.
  12. Total numbers of guidewires to complete
  13. LV lead placement.
  14. Guidewire-related adverse events.
  15. Procedural adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria/Exclusion Criteria:

  1. The patient is 18 years of age or older.
  2. The patient is clinically indicated for left ventricular lead placement as part of a pacing or defibrillator system.
  3. The patient may be safely exposed to magnetic fields that exist in Niobe® MNS laboratory.
  4. The patient is not participating in any clinical trial or studies that would conflict with the guidewire navigation/LV lead implant protocol for this study.
  5. The patient is not pregnant, and if of childbearing potential has completed a pregnancy test which resulted negative.
  6. The patient does not have an implanted pacemaker or defibrillator, unless such device will be explanted or otherwise deactivated during this procedure.
  7. The patient has no contraindications for contrast dye injection.
  8. The patient’s diastolic blood pressure is greater than 40 mm Hg.
  9. In the opinion of the investigator, the patient’s general health status does not preclude participation in the study.
  10. In the opinion of the investigator, the patient is a reasonable candidate for participation in this study.
  11. The patient is not expected to undergo a heart transplant in the next 6 months.
  12. The patient does not have a mechanical triscupid heart valve.
  13. The patient has not had a myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00370474

United States, Georgia
Northeast Georgia Heart Center
Gainesville, Georgia, United States, 30501
United States, Kentucky
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
United States, Massachusetts
Caritus St. Elizabeth's Hospital
Boston, Massachusetts, United States, 02135
United States, Tennessee
Baptist Memphis Hospital
Memphis, Tennessee, United States, 38120
United States, Texas
Trinity Mother Frances
Tyler, Texas, United States, 75701
United States, Virginia
Medical Center of Virginia
Richmond, Virginia, United States, 23219
Sponsors and Collaborators
Principal Investigator: Kenneth Ellenbogen, MD Medical Center of Virginia, Richmond, VA Identifier: NCT00370474     History of Changes
Other Study ID Numbers: PM-CLIN 001
First Posted: August 31, 2006    Key Record Dates
Last Update Posted: June 18, 2007
Last Verified: June 2007

Keywords provided by Stereotaxis:
Bi-V lead
Magnetic Navigation
Cardiac Resynchronization Therapy